COMMUNIQUÉS West-GlobeNewswire

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider
26/03/2025
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of directors to carry out a [...]
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
26/03/2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage [...]
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D
26/03/2025
AZURE-1 will evaluate the efficacy and safety of brelovitug compared to delayed treatment REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics , a clinical-stage biopharmaceutical company [...]
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
26/03/2025
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive [...]
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
26/03/2025
Company’s 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi- [...]
Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed
26/03/2025
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a crucial aspect of total wellbeing. Prime Biome Gummies have attracted a lot of attention in the [...]
Zelluna ASA [ZLNA]: Share capital increase resolution
26/03/2025
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the " Company "), where it was resolved to carry [...]
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
26/03/2025
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
26/03/2025
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Aligos Therapeutics Presents Positive Data at APASL 2025
26/03/2025
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]
Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025
26/03/2025
PARAMUS, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal [...]
Catheter Precision to Participate in and Share Data at Upcoming Industry Conferences
26/03/2025
FORT MILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
26/03/2025
Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
26/03/2025
These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3), show the potential for Decoy’s novel platform to address both significant [...]
Sofwave to Participate in Upcoming Conferences
26/03/2025
SAN CLEMENTE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, [...]
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
26/03/2025
NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
26/03/2025
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
26/03/2025
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management [...]
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
26/03/2025
SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor [...]

Pages